This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.

https://www.barrons.com/articles/pfizer-q1-earnings-covid-a6801d36

Pfizer Stock Jumps After Sales Beat. There’s More Good News From Earnings.

By
Josh Nathan-Kazis and
Jack Denton
  • Order Reprints
  • Print Article

Pfizer delivered a solid set of first-quarter results, with earnings largely in line with analysts’ estimates and revenue far ahead of expectations. There’s more good news: Amid speculation that Covid-19 sales may fall short this year, the pharma giant reaffirmed its 2023 outlook.

Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.